Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer

E. C. Bradley, G. P. Schechter, M. J. Matthews, J. Whang-Peng, M. H. Cohen, P. A. Bunn, D. C. Ihde, J. D. Minna

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Eight patients with small cell bronchogenic carcinoma treated with intensive combination chemotherapy, with and without radiotherapy, have been followed for a minimum of two and a half years without relapse. One patient, after a prodrome of macrocytic sideroblastic anemia, leukopenia, and thrombocytopenia, experienced erythroleukemia 34 months after starting chemotherapy, and cytogenetic studies revealed extensive chromosomal abnormalities. Another patient had persistent macrocytic anemia and pancytopenia two years after cessation of therapy. The remaining six patients have normal peripheral blood smears and cell counts. A significant incidence of preleukemia syndromes and acute leukemia appearing as late complications in intensively treated small cell lung cancer patients requires confirmation in larger series of long-term survivors. Prospective determination of marrow karyotype abnormalities may help to identify patients at greatest risk for developing secondary leukemia.

Original languageEnglish (US)
Pages (from-to)221-223
Number of pages3
JournalCancer
Volume49
Issue number2
StatePublished - 1982

Fingerprint

Leukemia, Erythroblastic, Acute
Small Cell Lung Carcinoma
Survivors
Macrocytic Anemia
Leukemia
Therapeutics
Preleukemia
Sideroblastic Anemia
Pancytopenia
Small Cell Carcinoma
Blood Cell Count
Bronchogenic Carcinoma
Leukopenia
Combination Drug Therapy
Karyotype
Cytogenetics
Chromosome Aberrations
Thrombocytopenia
Radiotherapy
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bradley, E. C., Schechter, G. P., Matthews, M. J., Whang-Peng, J., Cohen, M. H., Bunn, P. A., ... Minna, J. D. (1982). Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer, 49(2), 221-223.

Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. / Bradley, E. C.; Schechter, G. P.; Matthews, M. J.; Whang-Peng, J.; Cohen, M. H.; Bunn, P. A.; Ihde, D. C.; Minna, J. D.

In: Cancer, Vol. 49, No. 2, 1982, p. 221-223.

Research output: Contribution to journalArticle

Bradley, EC, Schechter, GP, Matthews, MJ, Whang-Peng, J, Cohen, MH, Bunn, PA, Ihde, DC & Minna, JD 1982, 'Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer', Cancer, vol. 49, no. 2, pp. 221-223.
Bradley EC, Schechter GP, Matthews MJ, Whang-Peng J, Cohen MH, Bunn PA et al. Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer. 1982;49(2):221-223.
Bradley, E. C. ; Schechter, G. P. ; Matthews, M. J. ; Whang-Peng, J. ; Cohen, M. H. ; Bunn, P. A. ; Ihde, D. C. ; Minna, J. D. / Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. In: Cancer. 1982 ; Vol. 49, No. 2. pp. 221-223.
@article{f91938bfa55740f1a6718420fcca3b74,
title = "Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer",
abstract = "Eight patients with small cell bronchogenic carcinoma treated with intensive combination chemotherapy, with and without radiotherapy, have been followed for a minimum of two and a half years without relapse. One patient, after a prodrome of macrocytic sideroblastic anemia, leukopenia, and thrombocytopenia, experienced erythroleukemia 34 months after starting chemotherapy, and cytogenetic studies revealed extensive chromosomal abnormalities. Another patient had persistent macrocytic anemia and pancytopenia two years after cessation of therapy. The remaining six patients have normal peripheral blood smears and cell counts. A significant incidence of preleukemia syndromes and acute leukemia appearing as late complications in intensively treated small cell lung cancer patients requires confirmation in larger series of long-term survivors. Prospective determination of marrow karyotype abnormalities may help to identify patients at greatest risk for developing secondary leukemia.",
author = "Bradley, {E. C.} and Schechter, {G. P.} and Matthews, {M. J.} and J. Whang-Peng and Cohen, {M. H.} and Bunn, {P. A.} and Ihde, {D. C.} and Minna, {J. D.}",
year = "1982",
language = "English (US)",
volume = "49",
pages = "221--223",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer

AU - Bradley, E. C.

AU - Schechter, G. P.

AU - Matthews, M. J.

AU - Whang-Peng, J.

AU - Cohen, M. H.

AU - Bunn, P. A.

AU - Ihde, D. C.

AU - Minna, J. D.

PY - 1982

Y1 - 1982

N2 - Eight patients with small cell bronchogenic carcinoma treated with intensive combination chemotherapy, with and without radiotherapy, have been followed for a minimum of two and a half years without relapse. One patient, after a prodrome of macrocytic sideroblastic anemia, leukopenia, and thrombocytopenia, experienced erythroleukemia 34 months after starting chemotherapy, and cytogenetic studies revealed extensive chromosomal abnormalities. Another patient had persistent macrocytic anemia and pancytopenia two years after cessation of therapy. The remaining six patients have normal peripheral blood smears and cell counts. A significant incidence of preleukemia syndromes and acute leukemia appearing as late complications in intensively treated small cell lung cancer patients requires confirmation in larger series of long-term survivors. Prospective determination of marrow karyotype abnormalities may help to identify patients at greatest risk for developing secondary leukemia.

AB - Eight patients with small cell bronchogenic carcinoma treated with intensive combination chemotherapy, with and without radiotherapy, have been followed for a minimum of two and a half years without relapse. One patient, after a prodrome of macrocytic sideroblastic anemia, leukopenia, and thrombocytopenia, experienced erythroleukemia 34 months after starting chemotherapy, and cytogenetic studies revealed extensive chromosomal abnormalities. Another patient had persistent macrocytic anemia and pancytopenia two years after cessation of therapy. The remaining six patients have normal peripheral blood smears and cell counts. A significant incidence of preleukemia syndromes and acute leukemia appearing as late complications in intensively treated small cell lung cancer patients requires confirmation in larger series of long-term survivors. Prospective determination of marrow karyotype abnormalities may help to identify patients at greatest risk for developing secondary leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0020066866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020066866&partnerID=8YFLogxK

M3 - Article

C2 - 6274504

AN - SCOPUS:0020066866

VL - 49

SP - 221

EP - 223

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -